Affymax ( OTCQB: AFFY ): Q2 EPS of $0.19. Press Release Post your comment!
(Reuters) - Drug maker Affymax Inc said it may consider selling itself or filing for bankruptcy among a range of strategic alternatives as it struggles with the recent recall of its sole commercial product, the anemia drug Omontys.
March 18 (Reuters) - Affymax Inc, which recalled its anemia drug Omontys in February, said it may consider selling itself or filing for bankruptcy among a range of strategic alternatives.
(Reuters) - Shares of Affymax Inc fell 85 percent after it said serious adverse reactions, including death, were reported among some of those using its sole commercial product, anemia drug Omontys.
Aranesp pressure was expected, and Epogen declines appear to be caused more by competition (albeit minimal) from Affymax 's AFFY Omontys and less from the decreased ESA usage due to bundled reimbursement that has plagued growth in previous quarters
operators DaVita DVA and Fresenius FMS, we think future biosimilar competition--as well as branded products like Affymax 's AFFY recently approved anemia drug Omontys--cloud Epogen's long-term prospects. We're forecasting continued double
sign for near-term sales. However, the DaVita deal only covers one third of the U.S. dialysis market, and Affymax 's AFFY Hematide--a more convenient and potentially cheaper option in a price-sensitive market--could receive Food
We are dropping coverage of Affymax AFFY to focus our resources elsewhere.
Affymax AFFY and partner Takeda announced Thursday their preliminary strategy toward ..... keeping our fair value estimate in place until we hear details regarding Affymax 's meeting with the FDA . As a reminder , the frequency of cardiovascular
lowering our fair value estimate for Affymax AFFY following the release of clinical ..... cardiovascular concerns), and we now think Affymax 's chances of winning approval ..... market for predialysis, we think Affymax and partner Takeda will need to